Cerevel Therapeutics Holdings, Inc. Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.

CERE

Classement en actions #2800
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm... Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing treatments for a range of neuroscience disorders. The company boasts a robust pipeline of therapeutic candidates currently undergoing various phases of clinical evaluation. Key assets include emraclidine, a positive allosteric modulator (PAM) in Phase 1b trials for schizophrenia. Another PAM, Darigabat, is being assessed in a Phase 2 proof-of-concept study for drug-resistant focal onset seizures in epilepsy, as well as in a Phase 1 trial for acute anxiety. For Parkinson's disease, Cerevel is advancing Tavapadon, a selective dopamine D1/D5 partial agonist, through Phase 3 clinical trials for both early and late stages of the condition. A related compound, CVL-871, also a selective dopamine D1/D5 partial agonist, is in Phase 2a trials for dementia-related apathy. The company's portfolio further includes CVL-936, a selective dopamine D3-preferring antagonist in Phase I for substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist targeting major depressive disorder and substance use disorder; and CVL-047, a selective PDE4 inhibitor also aimed at major depressive disorder and substance use disorder. Beyond individual compounds, Cerevel is actively developing an M4 agonist program for psychosis and related indications, alongside an LRRK2 inhibitor program designed to address the progression of Parkinson's disease. Founded in 2018, Cerevel Therapeutics is headquartered in Cambridge, Massachusetts.
Prix de l'action
$44.96
Dernière synchronisation: 2024-08-01
Capitalisation boursière
$6.67B
Changement (1 jour)
0.00%
Changement (1 an)
0.00%
Pays
US
Échange Cerevel Therapeutics Holdings, Inc. (CERE)

Catégorie

Healthcare
Historique des divisions d’actions pour Cerevel Therapeutics Holdings, Inc. (CERE)
L’action Cerevel Therapeutics Holdings, Inc. (symbole : CERE) a subi un total de 0 divisions.
La division la plus récente a eu lieu le Oct 21, 2026.
Une action CERE achetée avant le Oct 21, 2026 équivaudrait aujourd’hui à 0 actions CERE.
Liste des divisions d’actions
Année Division Multiplicateur Multiplicateur cumulatif
Pas assez de données pour les dates fournies.
Divisions d’actions d’entreprises similaires ou concurrentes
Entreprise Nombre de divisions d’actions Multiplicateur cumulatif Pays
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL